Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.036 | 0.7 |
mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.027 | 0.7 |
mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |